Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Olsen, Michael Hecht; Wachtell, Kristian; Beevers, Gareth; Dahlöf, Björn; Simone, Giovanni de; Devereux, Richard B.; Fairé, Ulf dé; Fyhrquist, F; Ibsen, Hans; Kjeldsen, Sverre E.; Lederballe‐Pedersen, Ole; Lindholm, Lars; Lyle, Paulette A.; Nieminen, Markku S.; Omvik, Per; Oparil, Suzanne; Wedel, Hans

doi:10.1097/hjh.0b013e32831daf96

Cited by 24 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, losartantreated individuals had significant LVH regression 48,49 and decrease in left atrial size 50,51 and decreased BNP. 52,53 They also had decreased platelet aggregation, decreased serum uric acid, 54 improved insulin sensitivity, 55 attenuated decline in HDL, 56 and decreased proteinuria. 57 All of these would be significant surrogate markers for improved cardiovascular risk.…”

Section: Losartan Intervention For Endpoint Reduction Trial As a Lookmentioning

confidence: 96%

Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

Ripley

Hirsch²

2010

IJNRD

View full text Add to dashboard Cite

Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago. During those years, researchers and clinicians have developed a growing base of knowledge on the benefits of losartan, particularly for hypertension and renal disease. These benefits include decreasing proteinuria, slowing the progression of diabetic nephropathy, controlling hypertension, and decreasing stroke risk in patients with left ventricular hypertrophy. Although many of the benefits of losartan represent a class effect for ARBs, losartan has pharmacokinetic and pharmacodynamic characteristics and effects that are unique and are not a class effect. For example, a shorter duration of action is seen with this first ARB compared with other more recently approved ARBs. Losartan also has a uricosuric effect not seen in other ARBs and attenuates platelet aggregation, which is not seen or is seen to a lesser extent with the other ARBs. This review presents the physiological effects of losartan on the kidney and discusses relevant clinical outcomes.

show abstract

Section: Losartan Intervention For Endpoint Reduction Trial As a Lookmentioning

confidence: 96%

Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

Ripley

Hirsch²

2010

IJNRD

View full text Add to dashboard Cite

show abstract

“…In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, HDL-C levels decreased less with losartan-based treatment than with atenolol-based treatment [41]. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), TC levels decreased more with amlodipine- and lisinopril-based treatment than with chlorthalidone-based treatment [42].…”

Section: Antihypertensive Agentsmentioning

confidence: 99%

Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases

Τζιόμαλος

Athyros²,

Karagiannis³

et al. 2011

TOCMJ

View full text Add to dashboard Cite

Dyslipidemia is a major vascular risk factor. Interestingly, several agents used for the prevention and treatment of vascular diseases have an adverse effect on the lipid profile. In addition, agents belonging to the same class (e.g. beta blockers) can have significantly different actions on lipid levels. We summarize the effects of drugs used for the prevention and treatment of vascular diseases on the lipid profile. These effects should be considered when selecting a specific agent, particularly in high-risk patients.

show abstract

“…Losartan was also shown to reduce brain natriuretic peptide to a significantly greater extent than atenolol in patients with hypertension with LVH . Relating to lipids, losartan attenuated high‐density lipoprotein cholesterol reduction during antihypertensive therapy, thus leading to higher high‐density lipoprotein cholesterol levels in the losartan compared with the atenolol group . This difference in high‐density lipoprotein cholesterol was associated with fewer end points, thus partly explaining the losartan‐related CVD benefits .…”

Section: Life Study: “Losartan Better Than Atenolol”mentioning

confidence: 99%

“…Relating to lipids, losartan attenuated high‐density lipoprotein cholesterol reduction during antihypertensive therapy, thus leading to higher high‐density lipoprotein cholesterol levels in the losartan compared with the atenolol group . This difference in high‐density lipoprotein cholesterol was associated with fewer end points, thus partly explaining the losartan‐related CVD benefits . Furthermore, lower high‐density lipoprotein cholesterol levels during the LIFE trial were associated with an increased risk for new‐onset DM …”

Section: Life Study: “Losartan Better Than Atenolol”mentioning

confidence: 99%

Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)—Lessons learned for losartan: An “old dog playing good tricks”

Katsiki

Tsioufis

Ural

et al. 2018

J of Clinical Hypertension

View full text Add to dashboard Cite

There is an unmet need to prevent cardiovascular disease and chronic kidney disease development and progression worldwide. Losartan, the first angiotensin receptor blocker, was shown to exert significant cardioprotective and renoprotective effects in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) and RENAAL (Reduction of Endpoints in NIDDM With the Angiotensin II Antagonist Losartan) trials. Losartan significantly prevented stroke and decreased serum uric acid levels and the rates of new-onset diabetes mellitus and atrial fibrillation. The present review discusses the LIFE (and its subanalyses) and RENAAL trials and the translation of their results to clinical practice. The place of losartan in the current guidelines for hypertension management is also discussed. Losartan still represents an efficacious, safe, and cost-effective therapeutic option in patients with hypertension who have left ventricular hypertrophy. Losartan is a useful antihypertensive agent for stroke prevention and in the management of patients with chronic kidney disease, atrial fibrillation, diabetes mellitus, albuminuria, and hyperuricemia.

show abstract

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Abstract: Losartan blunted the decrease in HDL cholesterol during antihypertensive treatment in the LIFE study. Higher intreatment HDL cholesterol was associated with fewer composite endpoints and may partly explain the better outcome of losartan-based treatment.

Cited by 24 publications

References 41 publications

Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases

Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)—Lessons learned for losartan: An “old dog playing good tricks”

Contact Info

Product

Resources

About